Table 2 Reduction in cell viability of MPM cells after incubation with Mapatumumab or Lexatumumab monoclonal antibodies. The percentage of reduction in cell viability was measured after incubation with 10 μg/ml Mapatumumab (Mapa) or Lexatumumab)Lexa) monoclonal antibodies. Data are expressed as mean ± s.d. from five independent experiments. **, P < 0.01 and *, P < 0.05 compared to untreated cells

MPM cell lines

10 μg/ml Mapa

10 μg/ml Lexa

Mapa and Lexa resistant (< 20% cell death)

H2052

3 ± 11

2 ± 9

SPC212

9 ± 5 *

7 ± 8

H226

5 ± 11

4 ± 6

more sensitive to Lexa

ZL5

9 ± 3 **

77+11 **

H2452

7 ± 3 **

52 ± 7 **

SDM4

9 ± 9

36 ± 9 **

SDM6

14 ± 14

37 ± 14 *

ZL34

8 ± 5 *

21 ± 10 **

SDM13

13 ± 3 *

22 ± 1 **

more sensitive to Mapa

H28

83 ± 2 **

66 ± 20 *

MSTO-211H

48 ± 6 **

24 ± 11 *

with similar sensitivity to Mapa and Lexa

SPC111

33 ± 14 **

31 ± 11 **

ZL55

31 ± 6 **

30 ± 9 **